

DEC 08 2003

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	09/966,939
Filing Date	September 28, 2001
First Named Inventor	Harry S. Sowden
Group Art Unit	1722
Examiner Name	Robert B. Davis
Attorney Docket Number	MCP-242

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ²
		Office ³	Number ⁴	KindCode ⁵				
RR		DE	27 10 307	0	Verfahren zur Herstellung von Verpackung von festen pharmazeutischen Dosisinheiten (English Abstract Attached)	09-15-1977	_____	/
RR		EP	0 088 556	A	Sumitomo Chemical Company Ltd.	09-14-1983	_____	
RR		EP	0 239 983	B1	Boehringer Ingelheim International GmbH (English Abstract Attached)	10-07-1987	_____	
RR		EP	0 294 993	B1	Pfizer Inc.	7/1/1991 12/14/1991-1/2/92	_____	
RR		EP	0 481 547	A1	Unilever PLC	04-22-1992	_____	
RR		EP	0 788 790	A2	Jagotec AG	02-06-1993 8/97	_____	
RR		EP	0 861 659	A1	University of Kentucky Research Foundation	02-21-1992 9/21/1998	_____	
RR		EP	0 950 402	B1	McNeil-PPC, Inc.	02-22-1993-5/03	_____	
RR		EP	1 077 065	A1	Chugai Seiyaku Kabushiki Kaisha	02-21-2001	_____	
RR		GB	994 742	A	The Wellcome Foundation Limited	05-04-1964-6/65	_____	
RR		GB	888 038	A	The Wander Company	01-24-1962	_____	
RR		GB	936 386	A	The Wellcome Foundation Limited	09-11-1963	_____	
RR		GB	1 144 915	A	Armour Pharmaceutical Company	03-12-1969	_____	
RR		GB	1 372 040	A	Boehringer Ingelheim	10-30-1974	_____	
RR		GB	1 510 772	A	ACO Lakemedel AB	05-17-1978	_____	
RR		GB	2 197 778	A	Katjes Fassin GmbH & Co. KG	06-02-1988	_____	
RR		WO	94/06416	A1	Ubaldo Conta et al.	03-31-1994	_____	
RR		WO	95/02396	A1	Smithkline Beecham Corporation	01-26-1995	_____	
RR		WO	97/06695	A1	The Procter & Gamble Company	02-27-1997	_____	
RR		WO	97/15293	A2	BASF Aktiengesellschaft	05-01-1997	_____	
RR		WO	99/51209	A1	Impax Pharmaceuticals, Inc.	10-14-1999	_____	
RR		WO	99/56730	A1	Alza Corporation	11-11-1999	_____	
RR		WO	00/18447	A2	Impax Pharmaceuticals, Inc.	04-06-2000	_____	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RR		LACHMAN, Leon et al., "Chapter II - Tablets", The Theory and Practice of Industrial Pharmacy, (1986), pp. 293-345	
RR		Examiner Signature <i>[Signature]</i>	Date Considered 1/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1,510,772

BEST AVAILABLE COPY



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
RP		3,146,169		D. Stephenson et al.	08-25-1964	_____
RP		4,139,589		Monique Beringer et al.	02-13-1979	_____
RP		4,230,693		Henry J. Izzo et al.	10-28-1980	_____
RP		4,271,206		Harry F. Fariel et al.	06-02-1981	_____
RP		4,273,793		Harry F. Fariel et al.	06-16-1981	_____
RP		4,372,942		Paul A. Cimiluca	02-08-1983	_____
RP		4,686,212		Fred P. Ducatman et al.	08-11-1987	_____
RP		4,749,575		Avner Rotman	06-07-1988	_____
RP		4,757,090		Anil M. Salpekar et al.	07-12-1988	_____
RP		4,762,719		Mark Forester	08-09-1988	_____
RP		4,851,226		Thomas N. Julian et al.	07-25-1989	_____
RP		4,882,167		Choong-Gook Jang	11-21-1989	_____
RP		4,929,446		Raymond A. Bartolucci	05-29-1990	_____
RP		4,980,169		Alfred Oppenheimer et al.	12-25-1990	_____
RP		5,075,114		Edward J. Roche	12-24-1991	_____
RP		5,213,808		Daniel Ba-Shalom et al. Bar - Shalom et al.	05-25-1993	_____
RP		5,368,863		James B. Eckenhoff et al.	11-29-1994	_____
RP		5,391,378		Richard Sanderson	02-21-1995	_____
RP		5,489,436		Michael R. Hoy et al.	02-06-1996	_____
RP		5,578,336		Woodrow C. Monta	11-26-1996	_____
RP		5,614,207		Manoj N. Shah et al.	03-25-1997	_____
RP		5,681,584		Louis Savastano et al.	10-28-1997	_____
RP		5,853,760		Karsten Cremer	12-29-1998	_____
RP		5,871,781		Garry L. Myers et al.	02-16-1999	_____
RP		6,103,257		Keith Nisonoff	08-15-2000	_____
RP		6,149,939		Matthew A. Strumov et al.	11-21-2000	_____
RP		6,200,590		John G. Eley	03-13-2001	_____
RP		6,248,760		Paul C. Wilhelmsen	06-19-2001	_____
RP		6,365,185		Wolfgang A. Ritschel et al.	04-02-2002	_____
RP		2001/0001260	A1	Liang-Chang Dong et al.	05-17-2001	_____
RP		2002/0028240	A1	Toyohiro Sawada et al.	03-07-2002	_____

Examiner Signature

Date Considered

1/29/04

BEST AVAILABLE COPY